» Articles » PMID: 32968282

Functional Genomic Landscape of Cancer-intrinsic Evasion of Killing by T Cells

Abstract

The genetic circuits that allow cancer cells to evade destruction by the host immune system remain poorly understood. Here, to identify a phenotypically robust core set of genes and pathways that enable cancer cells to evade killing mediated by cytotoxic T lymphocytes (CTLs), we performed genome-wide CRISPR screens across a panel of genetically diverse mouse cancer cell lines that were cultured in the presence of CTLs. We identify a core set of 182 genes across these mouse cancer models, the individual perturbation of which increases either the sensitivity or the resistance of cancer cells to CTL-mediated toxicity. Systematic exploration of our dataset using genetic co-similarity reveals the hierarchical and coordinated manner in which genes and pathways act in cancer cells to orchestrate their evasion of CTLs, and shows that discrete functional modules that control the interferon response and tumour necrosis factor (TNF)-induced cytotoxicity are dominant sub-phenotypes. Our data establish a central role for genes that were previously identified as negative regulators of the type-II interferon response (for example, Ptpn2, Socs1 and Adar1) in mediating CTL evasion, and show that the lipid-droplet-related gene Fitm2 is required for maintaining cell fitness after exposure to interferon-γ (IFNγ). In addition, we identify the autophagy pathway as a conserved mediator of the evasion of CTLs by cancer cells, and show that this pathway is required to resist cytotoxicity induced by the cytokines IFNγ and TNF. Through the mapping of cytokine- and CTL-based genetic interactions, together with in vivo CRISPR screens, we show how the pleiotropic effects of autophagy control cancer-cell-intrinsic evasion of killing by CTLs and we highlight the importance of these effects within the tumour microenvironment. Collectively, these data expand our knowledge of the genetic circuits that are involved in the evasion of the immune system by cancer cells, and highlight genetic interactions that contribute to phenotypes associated with escape from killing by CTLs.

Citing Articles

Mediates Immunosuppression of the Tumor Microenvironment in Non-Small Cell Lung Cancer.

Fan Y, Ji X, Yuan K, Wu Q, Lou M J Inflamm Res. 2025; 18:3333-3347.

PMID: 40078575 PMC: 11900795. DOI: 10.2147/JIR.S509316.


PCBP2 promotes immune evasion via cGAS-STING pathway in biochemical recurrence of prostate cancer.

Zhou Z, Li T, Zhang Y, Zhou X, Song X, Ji S APL Bioeng. 2025; 9(1):016112.

PMID: 40051782 PMC: 11884866. DOI: 10.1063/5.0250173.


Massively parallel in vivo Perturb-seq screening.

Zheng X, Thompson P, White C, Jin X Nat Protoc. 2025; .

PMID: 39939709 DOI: 10.1038/s41596-024-01119-3.


Development of a novel prognostic signature based on cytotoxic T lymphocyte-evasion genes for hepatocellular carcinoma patient management.

Zhu Q, Liao S, Wei T, Liu S, Yang C, Tang J Discov Oncol. 2025; 16(1):144.

PMID: 39928212 PMC: 11811355. DOI: 10.1007/s12672-025-01909-5.


Evolutionary trajectories of immune escape across cancers.

Chen W, Baker T, Zhang Z, Ogilvie H, Van Loo P, Gu S bioRxiv. 2025; .

PMID: 39868264 PMC: 11761017. DOI: 10.1101/2025.01.17.632799.


References
1.
Chen D, Mellman I . Elements of cancer immunity and the cancer-immune set point. Nature. 2017; 541(7637):321-330. DOI: 10.1038/nature21349. View

2.
Hegde P, Chen D . Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020; 52(1):17-35. DOI: 10.1016/j.immuni.2019.12.011. View

3.
Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5):541-550. PMC: 5998822. DOI: 10.1038/s41591-018-0014-x. View

4.
Hugo W, Zaretsky J, Sun L, Song C, Moreno B, Hu-Lieskovan S . Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016; 165(1):35-44. PMC: 4808437. DOI: 10.1016/j.cell.2016.02.065. View

5.
Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View